SCHEDULE 13G/A: Dr. Arie Belldegrun and Affiliated Entities Disclose 5.8% Stake in Allogene Therapeutics

Dr. Arie Belldegrun and several affiliated investment entities have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 5.8% of Allogene Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Dr. Arie Belldegrun, individually and through affiliated entities, reported beneficial ownership of 12,393,567 shares of Allogene Therapeutics, Inc. common stock as of December 31, 2024.
• This aggregate ownership represents 5.8% of the company's outstanding common stock.
• Dr. Belldegrun's reported beneficial ownership includes 3,118,104 shares issuable from stock options and 70,658 shares from Restricted Stock Units, both exercisable/releasable within 60 days of December 31, 2024.
• The total also encompasses shares held by entities managed or controlled by Dr. Belldegrun or where he is a Senior Managing Director, specifically: Bellco Legacy IV LLC (4,710,120 shares, 2.2%), Bellco Legacy LLC (539,867 shares, 0.3%), Vida Ventures LLC (1,798,163 shares, 0.8%), Vida Ventures III, L.P. (1,720,172 shares, 0.8%), and Vida Ventures III-A, L.P. (3,965 shares, 0.0%).
• The percentage of class is calculated based on 209,672,091 shares of common stock outstanding as of November 1, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 7, 2024.
• This filing is an Amendment No. 5 to a previously filed Schedule 13G.

Sentiment

Score: 6

Explanation: The document is a factual disclosure of beneficial ownership. The continued significant stake by a key individual and associated entities can be viewed as a positive signal of confidence, leading to a slightly positive sentiment.

Positives

• The continued significant beneficial ownership by Dr. Arie Belldegrun, a key figure associated with the company, and his affiliated investment entities, may signal ongoing confidence in Allogene Therapeutics' long-term prospects.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Dr. Arie Belldegrun's beneficial ownership includes shares held by Bellco Legacy LLC and Bellco Legacy IV LLC, which are limited liability companies managed or controlled by him and Rebecka Belldegrun.
• His beneficial ownership also includes shares held by Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P., where Dr. Belldegrun serves as a Senior Managing Director of the managing entities.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes by a key individual and affiliated investment funds, which can influence investor perception and confidence.

Key Dates

Keywords

Allogene Therapeutics, Arie Belldegrun, Beneficial Ownership, Schedule 13G, Common Stock, SEC Filing, Institutional Ownership, Biotechnology, Pharmaceuticals